Genexi Biotech Accelerator Starts an ICO

This is a paid-for submitted press release. CCN does not endorse, nor is responsible for any material included below and isn’t responsible for any damages or losses connected with any products or services mentioned in the press release. CCN urges readers to conduct their own research with due diligence into the company, product or service mentioned in the press release.

On June 1, 2018, GENEXI Biotech Accelerator will launch a public token sale, during which GEN tokens will be sold. The project plans to raise from 20 to 70 million dollars.

The GENEXI ecosystem is a niche digital space which offers an innovative solution for the e-commerce market which will bring biotech producers, distributors, retailers and end-consumers together, and will facilitate cross-industry operations within the whole ecosystem. This constellation of high-tech, blockchain-based solutions ensures absolute transparency throughout the supply chain, from the manufacturer to the end seller, automates as much of the supply system as possible, eliminates middlemen, lowers costs, and guarantees protection from counterfeiting and fraud.

“Traditionally, blockchain is associated with the financial sector, but in healthcare this technology can be implemented just as widely,” says GENEXI’s founder Alexey Zhelyaskov, “It solves all current problems with pharmaceutical distribution, allows you to track the supply chain for each batch of any drug, eliminate fraud, quickly conclude standard contracts and safely process payments, give easy access to the global market and retail chains for small companies, and store large volumes of data at the maximum level of security”.

“Blockchain has an amazing future in the medical field,” – adds Alexey. “It doesn’t just help create new pharmaceuticals and distribute them, it also opens vast opportunities for new projects by working with massive data sets and making it easier to raise funds.”

Seeing the potential of implementing blockchain in healthcare, in September 2017 Alexey founded GENEXI Biotech Accelerator. GENEXI team includes, among others, professional experts in biomedicine, digital health, life sciences, pharmaceuticals, downstream chemical processing, agriculture and bioservices. GENEXI Foundation will provide research, business development and marketing support to these projects to ensure their further development. By working across industry, academia, and the business community GENEXI Foundation offers funding for projects that will benefit the society at large. “The GENEXI ecosystem is designed to promote innovative and revolutionary pharmaceutical and biotechnological projects, as well as embedding the blockchain technology into existing healthcare practices. Biotech projects are able to reach their logical conclusion using grant funding and then, as the finishing touches are still being applied, gain access to networks of distributors and retailers, which immediately put the new product into circulation as soon as they have capacity,” – Alexey comments.

From its very first day, GENEXI was involved in supporting real projects in regenerative pharmacology and handful of projects that will bring new hope to people suffering from conditions like Alzheimer’s disease and support cancer control efforts. Crowdfunding, as a growing trend, will help fund hundreds of thousands of biotech projects and will have a huge impact on entrepreneurs generally. In order to fund new projects and expand GENEXI’s ecosystem to a global scale, the company has announced that it will raise funds from private token holders.

GENEXI Biotech Accelerator has issued 12 billion GEN tokens, 70% of which will be offered for sale. The ICO will last 2 months, from June 1st to July 31st, 2018. The minimum amount of funds the company plans to raise is $20 million, with an upper goal of about $70 million. Part of the funds raised will be directed toward grants for promising biotech projects, the rest will go to development of the ecosystem, marketing and launching of pharmaceutical products. If GENEXI reaches its hard cap of $70 million, it will raffle off 3 grants with simplified terms, for a total value of $100,000, among biotech labs and companies that will have expressed the willingness to partner with Genexi before the end of the crowdfunding campaign.

There’s a system of bonuses for early buyers. Those buying tokens May 1–31 will get the best deal, with a bonus of 20%; on June 1–14 the bonus will be 17%, on June 15–28 – 9%, June 29 – July 12 – 5%, then 2% until the end of the initial offering.

For more information, please see the official site:





Source link

Related Posts